|
|
|
|
| LEADER |
01750nam a2200265Ia 4500 |
| 001 |
10.2217-fon-2022-0095 |
| 008 |
220706s2022 CNT 000 0 und d |
| 020 |
|
|
|a 14796694 (ISSN)
|
| 245 |
1 |
0 |
|a Real-world cost-effectiveness of primary prophylaxis with G-CSF biosimilars in patients at intermediate/high risk of febrile neutropenia
|
| 260 |
|
0 |
|b Future Medicine Ltd.
|c 2022
|
| 856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.2217/fon-2022-0095
|
| 520 |
3 |
|
|a Background: Real-world data suggests superiority of pegfilgrastim (PEG) over filgrastim (FIL) in reducing the incidence of chemotherapy-induced febrile neutropenia (FN), probably attributable to underdosed FIL in practice. We used real-world data to assess the cost-effectiveness of primary prophylaxis with PEG versus FIL in cancer patients at intermediate-to-high risk of FN from a US payer perspective. Methods: A Markov model with lifetime horizon. Results: For the high-risk group, PEG (vs FIL) biosimilars resulted in 0.43 FN events prevented (FNp), 0.27 quality-adjusted life-years gained (QALYg) and a cost saving of USD
|5 703. For the intermediate-risk group, PEG biosimilar led to 0.18 FNp and 0.12 QALYg, at USD
|9 674/FNp and USD
|1 4,502/QALYg. Conclusion: PEG biosimilars may provide opportunities to optimize FN management in patients with intermediate-to-high FN risk. © 2022 Pfizer Inc.
|
| 650 |
0 |
4 |
|a Biosimilar
|
| 650 |
0 |
4 |
|a Cancer
|
| 650 |
0 |
4 |
|a Cost-effectiveness analysis
|
| 650 |
0 |
4 |
|a Filgrastim
|
| 650 |
0 |
4 |
|a G-CSF
|
| 650 |
0 |
4 |
|a Pegfilgrastim
|
| 700 |
1 |
0 |
|a Cornes, P.
|e author
|
| 700 |
1 |
0 |
|a Kelton, J.
|e author
|
| 700 |
1 |
0 |
|a Liu, R.
|e author
|
| 700 |
1 |
0 |
|a Stephens, J.
|e author
|
| 700 |
1 |
0 |
|a Yang, J.
|e author
|
| 700 |
1 |
0 |
|a Zaidi, O.
|e author
|
| 773 |
|
|
|t Future Oncology
|
